The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Urology

• Publication date

  1996-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(01)66315-8PMID 8583582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo.

  2009cited by this paper
• Papaverine-induced erection

  2006cited by this paper
• Intracavernous injection of vasoactive drugs in the rabbit

  2004cited by this paper
• Nitric oxide modulates angiogenesis elicited by prostaglandin E1 in rabbit cornea.

  1995cited by this paper
• [Results of color-coded duplex ultrasound diagnosis (angiodynography) after intraurethral administration of PgE1 in erectile dysfunction].

  1995cited by this paper
• Ergebnisse der Color-coded-duplex-Sonographie (Angiodynographie) nach intraurethraler Applikation von Pg E1 bei ED

  1995cited by this paper
• Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum.

  1994cited by this paper
• The performance of the Rigiscan in the measurement of penile tumescence and rigidity.

  1994cited by this paper
• Problems and conflicts in peer review.

  1994cited by this paper
• Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction.

  1993cited by this paper
• Intracavernous papaverine for impotence in spinal cord injured patients

  1993cited by this paper
• Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.

  1993cited by this paper
• Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction.

  1993cited by this paper
• [Effectiveness and safety of cavernous body auto-injection therapy with papaverine/phentolamine. Study group].

  1993cited by this paper
• A prostaglandin E1 dose-response study in man.

  1993cited by this paper
• Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients.

  1993cited by this paper
• Komplikation vasoaktiver Substanzen in der Diagnostik und Therapie der erektilen Dysfunktion (ED): Erfahrungen an weit über 2000 Patienten

  1993cited by this paper
• A comparative study with intracavernous injection of prostaglandin E1 versus papaverine for the diagnostic assessment of erectile impotence.

  1992cited by this paper
• Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.

  1992cited by this paper
• [Intracavernous self-injection in impotence].

  1992cited by this paper
• The combined intracavernous injection and stimulation test: diagnostic accuracy.

  1992cited by this paper
• [Cardiopulmonary effects of prostaglandin E1. Aspects of drug safety].

  1992cited by this paper
• [Long-term results of corpus cavernosum auto-injection therapy in treatment of patients with chronic erectile dysfunction].

  1992cited by this paper
• Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1.

  1992cited by this paper
• Effect of prostaglandin E on immune function in normal healthy volunteers.

  1992cited by this paper
• [Double-blind trial of oral prostaglandin E1 on impotence].

  1992cited by this paper
• Risk factors for papaverine-induced priapism.

  1992cited by this paper
• SCHWELLKORPER-AUTOINJEKTIOSTHERAPIE (=SKAT) BEI IMPOTENZ

  1992cited by this paper
• [Controlled long-term blood pressure measurement with intravenous prostaglandin E1 infusion].

  1991cited by this paper
• Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.

  1991cited by this paper
• [Acceptance of corpus cavernosum auto-injection therapy in long-term treatment of erectile dysfunction].

  1991cited by this paper
• An improved vasoactive drug combination for a pharmacological erection program.

  1991cited by this paper
• 13,14-dihydro-PGE1 (PGE0) but not 15-keto-PGE1 is a Potent Inhibitor of Human Platelet and Neutrophil Activation

  1991cited by this paper
• Pharmacologically induced erections among geriatric men.

  1991cited by this paper
• Therapeutic Efficacy of Intravenous Prostaglandin E1 Versus Pentoxifylline in Patients with Intermittent Claudication

  1991cited by this paper
• Evaluation of I-C Papaverine in Patients with Psychogenic and Organic Impotence

  1991cited by this paper
• A new view of prostaglandin E regulation of the immune response.

  1991cited by this paper
• Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.

  1991cited by this paper
• Pharmacological erection program using prostaglandin E1.

  1991cited by this paper
• Intracavernous injection of prostaglandin E1: the application to cavernosography and penile blood flow measurement for the diagnosis of venogenic impotence.

  1991cited by this paper
• [Corpus cavernosum injection treatment of erectile impotence].

  1990cited by this paper
• E-series prostaglandins and arginine vasopressin in the modulation of male sexual behavior.

  1990cited by this paper
• Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism.

  1990cited by this paper
• Inhibition of Tumor Growth and Metastasis by Chronic Intravenous Infusion of Prostaglandin E1

  1990cited by this paper
• Prostaglandin E1 therapy for impotence, comparison with papaverine.

  1990cited by this paper
• Classification of sexual dysfunction for management of intracavernous medication-induced erections.

  1990cited by this paper
• Intracavernous injection therapy: analysis of results and complications.

  1990cited by this paper
• Intracavernous papaverine in the management of psychogenic impotence.

  1990cited by this paper
• Therapieergebnisse mit PGE1 bei erektiler Dysfunktion

  1990cited by this paper
• Medical treatment of impotence with papaverine and phentolamine intracavernosal injection.

  1990cited by this paper
• NORADRENALINE RELEASE IN HUMAN CORPUS CAVERNOSUM AND ITS MODULATION VIA PRESYNAPTIC α2‐ADRENOCEPTORS

  1989cited by this paper
• Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction.

  1989cited by this paper
• Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection.

  1989cited by this paper
• [Priapism as a complication following diagnostic papaverine test].

  1989cited by this paper
• Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence.

  1989cited by this paper
• Characterization of contraction-mediating prostanoid receptors in human penile erectile tissues.

  1989cited by this paper
• Changes in Penile Hemodynamics after Intracavernous Injection of Prostaglandin E1 and Prostaglandin I2 in Pigtailed Monkeys

  1989cited by this paper
• Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates.

  1989cited by this paper
• Regulation of adrenergic activity in penile corpus cavernosum.

  1989cited by this paper
• Injections of Papaverine and Regitine Into the Corpora Cavernosa for Erectile Dysfunction: Clinical Results in 60 Patients

  1989cited by this paper
• Injections of papaverine and regitine into the corpora cavernosa for erectile dysfunction: clinical results in 60 patients.

  1989cited by this paper
• Effects of endogenous and synthetic prostanoids, the thromboxane A2 receptor agonist U‐46619 and arachidonic acid on [3H]‐noradrenaline release and vascular tone in rat isolated kidney

  1989cited by this paper
• [Prostaglandin E1 in erectile dysfunction].

  1989cited by this paper
• Impotence evaluated by the use of prostaglandin E1.

  1989cited by this paper
• Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence.

  1989cited by this paper
• The pH analysis of papaverine-phentolamine and prostaglandin E1 for pharmacologic erection.

  1989cited by this paper
• Why do so many people drop out from auto-injection therapy for impotence?

  1989cited by this paper
• Diagnosis of male impotence after intracavernous papaverine test.

  1988cited by this paper
• Intracavernous self-injection for erectile failure.

  1988cited by this paper
• [Open multicenter study of the differential diagnosis of erectile dysfunction with a papaverine-phentolamine combination (BY023)].

  1988cited by this paper
• Intracavernous injection of papaverine, phentolamine and phenoxybenzamine.

  1988cited by this paper
• Pharmacologically induced erection in patients with multiple sclerosis.

  1988cited by this paper
• Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs.

  1988cited by this paper
• Intravenöse Prostavasin-Therapie bei peripherarteriellen Durchblutungsstörungen im Fontaine-Stadium III und IV. Früh- und Spätergebnisse einer Screening-Studie

  1988cited by this paper
• Hemodynamic and angiographic effects of prostaglandin E1 in coronary artery disease.

  1988cited by this paper
• [Value of prostaglandin El in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction].

  1988cited by this paper
• Zur Wirkung von Prostaglandin E1 auf Kollateralarterien bei arterieller Verschlußkrankheit

  1988cited by this paper
• Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence.

  1988cited by this paper
• Intracavernous injection of prostaglandin E1 in impotent men.

  1988cited by this paper
• Intracavernous self-injection for impotence: a long-term therapeutic option? Experience in 78 patients.

  1988cited by this paper
• Pharmacological erection: diagnosis and treatment applications in 69 patients.

  1987cited by this paper
• The erectile angle: objective criterion to evaluate the papaverine test in impotence.

  1987cited by this paper
• The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury.

  1987cited by this paper
• Papaverine testing of impotent patients following nerve-sparing radical prostatectomy.

  1987cited by this paper
• Diagnostic intracorporeal papaverine and erectile dysfunction.

  1987cited by this paper
• Prostaglandin E1 in Arterial Occlusive Disease in Stages III and IV According to Fontaine

  1986cited by this paper
• Long-Term Intravenous Infusion of PGE1 in Peripheral Arterial Blood Flow Disorders: Results of an Open Screening Study with Patients in Fontaine’s Stages III and IV

  1986cited by this paper
• Effect of chronic ingestion of a prostaglandin E analogue on immunologic function in healthy elderly subjects.

  1986cited by this paper
• Activation of suppressor cells by low molecular weight factors secreted by spleen cells of tumor-bearing mice: modulatory role of prostaglandins.

  1986cited by this paper
• Rationelle Diagnostik der erektilen Dysfunktion unter Anwendung eines pharmakologischen Testes

  1986cited by this paper
• Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarinic control and pathological implications.

  1986cited by this paper
• Inhibition of Mitotic and Proliferative Activity of Smooth Muscle Cells by Prostaglandin E1

  1986cited by this paper
• Effects of Prostaglandins on Platelet Function Ex Vivo and in Animal Thrombosis Models

  1986cited by this paper
• Prostaglandin E1 in Atherosclerosis

  1986cited by this paper
• Biochemistry and Pharmacology of Prostaglandin E1: Introductory Remarks

  1986cited by this paper
• Intracorporal injection of papaverine and phentolamine in the management of impotence.

  1986cited by this paper
• Intracavernous injection of papaverine in paraplegic males.

  1986cited by this paper
• Prostaglandin synthetase inhibition of renal pelvic smooth muscle in the rabbit.

  1985cited by this paper
• Circulation parameters during intravenous and intra-arterial administration of increasing doses of prostaglandin E1 in healthy subjects

  1985cited by this paper
• [Effects of prostaglandin El on hemodynamics and metabolism of the extremities in healthy humans and patients with stage III and IV arterial occlusive disease].

  1985cited by this paper

• The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta‐analysis

  2025cites this paper
• [Priapism].

  2024cites this paper
• Erratum: The correlation between premature ejaculation and a high incidence of erectile dysfunction and its research progress: a narrative review

  2024cites this paper
• A novel strategy to induce penile erection during penile doppler ultrasound: oral sildenafil administration plus alprostadil injection

  2024influential citation
• The assessment and aetiology of drug-induced ischaemic priapism.

  2024cites this paper
• Unveiling the science behind erectile dysfunction topical therapy: investigating transdermal papaverine as a novel treatment approach.

  2024cites this paper
• Pain associated with prostaglandin E1‐containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy

  2024cites this paper
• A comprehensive history of injection therapy for erectile dysfunction, 1982-2023.

  2024cites this paper
• Current status of intracavernosal injection therapy in erectile dysfunction

  2023cites this paper
• A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

  2023cites this paper
• Long-term effects of combination treatment comprising low-intensity extracorporeal shockwave therapy and tadalafil for patients with erectile dysfunction: a retrospective study

  2023cites this paper
• Erectile Dysfunction: Key Role of Cavernous Smooth Muscle Cells

  2022cites this paper
• Sexual Dysfunction Among Patients With Chronic Kidney Disease.

  2021cites this paper
• Sexual Dysfunction in Patients with Neurologic Disorders

  2021cites this paper
• Sexual function in patients with CKD and ESRD

  2021cites this paper
• Pathophysiology and Grayscale Ultrasonography of Penile Corporal Fibrosis.

  2021cites this paper
• Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

  2021cites this paper
• Outcomes of low-flow priapism and role of integrated penile prosthesis management

  2021cites this paper
• Pharmacology and perspectives in erectile dysfunction in man.

  2020cites this paper
• The medical and surgical treatment of erectile dysfunction: a review and update.

  2020cites this paper
• Dysfunction of Sexual and Accessory Sex Organs

  2020cites this paper
• Lipid-based nanoparticles in the treatment of erectile dysfunction

  2020cites this paper
• Ionic Channels as Potential Therapeutic Targets for Erectile Dysfunction: A Review

  2020cites this paper
• The management of sexual dysfunction resulting from radiotherapy and androgen deprivation therapy to treat prostate cancer: A comparison of uro‐oncology practice according to disease stage

  2020cites this paper
• Priapizm Tedavisi: Tek Merkez Sonuçları

  2020cites this paper
• The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts

  2020cites this paper
• Drug delivery options and therapeutic advances in the management of erectile dysfunction

  2020cites this paper
• Diabetic Neuropathy and Clinical Practice

  2020cites this paper
• An update on the drug safety of treating erectile dysfunction

  2019cites this paper
• Reflexionen über 50 Jahre Sexualmedizin in der Urologie mit Fokus auf männliche Sexualstörungen

  2019cites this paper
• Erectile Dysfunction: A Primer for in Office Management

  2019cites this paper
• Treatment of Priapism Secondary to Drugs for Erectile Dysfunction

  2019cites this paper
• Sexual Dysfunction in Suprapontine Lesions

  2019cites this paper
• Current diagnosis and management of erectile dysfunction

  2019cites this paper
• Variability in Penile Duplex Ultrasound International Practice Patterns, Technique and Interpretation: An anonymous survey of ISSM members

  2018cites this paper
• Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.

  2018cites this paper
• British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017.

  2018cites this paper
• Topical alprostadil (Vitaros©) in the treatment of erectile dysfunction after non-nerve-sparing robot-assisted radical prostatectomy

  2018cites this paper
• Nebenwirkungen der medikamentösen Behandlung der erektilen Dysfunktion

  2017cites this paper
• Management of refractory ischemic priapism: current perspectives

  2017cites this paper
• [Side effects of erectile dysfunction drug treatment].

  2017cites this paper
• Sex and Chronic Physical Illness

  2017cites this paper
• El manejo del priapismo isquémico agudo: una revisión actualizada

  2017cites this paper
• The management of the acute ischemic priapism: A state of the art review.

  2017cites this paper
• Erectile Dysfunction , Premature Ejaculation , Penile Curvature and Priapism EAU Guidelines on

  2017cites this paper
• The medical treatment

  2017cites this paper
• Aging and Erectile Dysfunction.

  2016cites this paper
• Clinical Results of Penile Prosthesis Implantation for Treating Organic Erectile Dysfunction

  2016cites this paper
• The Clinical Results of Penile Prosthesis Implantation for the Treatment of Organic Erectile Dysfunction

  2016cites this paper
• Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation

  2016cites this paper
• Self-Injection, Transurethral, and Topical Therapy in Erectile Dysfunction

  2016cites this paper
• Sickle cell-induced ischemic priapism

  2016cites this paper
• A new type of erectile dysfunction treatment in the Czech Republic - the application of alprostadil cream

  2016cites this paper
• Erectile Dysfunction: An Update Review

  2015cites this paper
• Emergencies in Andrology

  2015cites this paper
• Guía de disfunción eréctil. Sociedad Colombiana de Urología

  2015cites this paper
• Factores que influyen en la respuesta a los inhibidores de la fosfodiesterasa tipo cinco en monoterapia frente a tratamiento combinado en el tratamiento de la disfunción eréctil

  2015cites this paper
• National practice patterns of treatment of erectile dysfunction with penile prosthesis implantation.

  2015cites this paper
• Guidelines on Priapism

  2015cites this paper
• Intracavernosal Injection for the Diagnosis, Evaluation, and Treatment of Erectile Dysfunction: A Review.

  2015cites this paper
• Emerging drugs for the treatment of erectile dysfunction

  2015cites this paper
• Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications

  2015cites this paper
• Penile Priapism, Clitoral Priapism, and Persistent Genital Arousal Disorder: A Contemporary Review.

  2015cites this paper
• Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?

  2014cites this paper
• Importancia de la rehabilitación precoz de los cuerpos cavernosos tras prostatectomía radical

  2014cites this paper
• Erectile dysfunction

  2014cites this paper
• Medical and Surgical Therapy of Erectile Dysfunction

  2014cites this paper
• Erectile Dysfunction and Infertility

  2014cites this paper
• The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors

  2014cites this paper
• [Pharmacology of misoprostol (pharmacokinetic data, adverse effects and teratogenic effects)].

  2014cites this paper
• Update on the Treatment of Erectile Dysfunction

  2014cites this paper
• A Preclinical Study of Novel Phentolamine Formulation and in Vitro/in Vivo Evaluation

  2014cites this paper
• European Association of Urology guidelines on priapism.

  2014cites this paper
• How to Treat Erectile Dysfunction in Men with Diabetes: from Pathophysiology to Treatment

  2014cites this paper
• Prophylactic Phenylephrine for Iatrogenic Priapism: A Pilot Study With Peyronie's Patients

  2014cites this paper
• Current Diagnosis and Management of Erectile Dysfunction

  2014cites this paper
• Management of erectile dysfunction in men treated with androgen deprivation therapy

  2013cites this paper
• Ultrastructural and morphometrical study of preimplantation endometrium in superovulated mice treated with progesterone or Sildenafil

  2013cites this paper
• LE TRAITEMENT MEDICAL DE LA DYSFONCTION ERECTILE EN L’AN 2000

  2013cites this paper
• Sexual quality of life in women partnered with men using intracavernous alprostadil injections after radical prostatectomy.

  2013cites this paper
• SOP conservative (medical and mechanical) treatment of erectile dysfunction.

  2013cites this paper
• Bioanalytical Assays : Gas Chromatography ( GC ) 30

  2013cites this paper
• Erectile Dysfunction: The Medical Treatment

  2013cites this paper
• Incidence of priapism in emergency departments in the United States.

  2013cites this paper
• Tratamento da Disfunção Erétil após Prostatectomia Radical

  2013cites this paper
• Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction

  2013cites this paper
• Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model

  2012influential citation
• The Role Erectile Dysfunction Plays in Cardiovascular Diseases

  2012cites this paper
• [Erectile dysfunction: conservative treatment and new approaches].

  2012cites this paper
• Evaluation and Management of Erectile Dysfunction

  2012cites this paper
• A review of outcomes of an intracavernosal injection therapy programme

  2012cites this paper
• Clinical outcomes of intracavernosal injection in postprostatectomy patients: a single-center experience.

  2012cites this paper
• A Comparative Review of the Options for Treatment of Erectile Dysfunction

  2012cites this paper
• Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction

  2012cites this paper
• Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy.

  2012cites this paper
• Looking to the Future for Erectile Dysfunction Therapies

  2012cites this paper
• Management of sexual dysfunction in Parkinson’s disease

  2011cites this paper
• Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction

  2011cites this paper
• From lab to Clinical Activity: Adrenergic Receptors and Human Uro-Genital Tissues

  2011cites this paper
• Self-Injection, Transurethral and Topical Therapy in Erectile Dysfunction

  2011cites this paper